Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ACE2 and TMPRSS2 genes were more highly expressed in tumors of elderly male cancer patients compared to healthy individuals, with notable differences across age and gender.

This study found that ACKR2 plays a crucial role in reducing inflammatory skin fibrosis and promoting inflammation resolution through IFN‐β production, limiting tissue scarring.

This review discusses the impact of ACE polymorphism on COVID-19 severity, suggesting it affects adults more than children, but presents mixed findings concerning infection prevalence and mortality.

This study found that PCOS women with COVID-19 had lower ACE2 levels and higher insulin resistance, suggesting increased cardiovascular risk.

This study found that increased ACE2 expression, prompted by mechanical stretch, promotes skin regeneration and reduces dermal thinning during tissue expansion by enhancing collagen synthesis, suggesting ACE2's potential to improve clinical outcomes in reconstructive surgery settings.

This study found that the enzyme Acer1 plays a crucial role in skin health and tumor prevention by regulating ceramide metabolism in mice.

Tocilizumab might be an effective treatment for COVID-19.

This review observes higher ACE2 expression in myocardial and lung tissues of heart failure and COPD patients but finds no link between RAAS inhibitors and COVID-19 severity.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

This study describes the prescribing habits of Spanish dermatologists, highlighting that topical minoxidil and oral finasteride are the most common treatments for male AGA and postmenopausal female AGA.

This study found that higher levels of AR expression are linked to a decreased risk of severe COVID-19 in females, and identified ACE2, MX1, and TMPRSS2 as important molecular markers for COVID-19 management.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.

This study found that loss of the ACER1 gene in mice led to increased ceramide levels and progressive hair loss, highlighting ACER1's role in maintaining hair follicle stem cell homeostasis.

This study reports new fluorogenic ceramidase substrates and highlights RBM14C24:1 as an efficient substrate for neutral ceramidase, while RBM15C18:1 is the best probe for measuring ACER1 and ACER2 activities, potentially aiding high-throughput screening for ceramidase inhibitors.

This review explores possible reasons for why male COVID-19 patients experience more severe symptoms and higher fatality rates than female patients but provides no new clinical results.

This review discusses biological sex differences in COVID-19 outcomes and reports no new clinical results; it identifies a need for studies to clarify how sex influences disease progression.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.

This review discusses the various skin lesions associated with COVID-19, which vary in type and severity, and reports that these lesions can appear before other symptoms and typically resolve spontaneously.

This review discusses potential mechanisms contributing to higher COVID-19 mortality among men, particularly the roles of smoking, genetic factors, and reproductive hormones, without presenting new clinical findings.

This paper discusses the variability in COVID-19 susceptibility and severity, emphasizing factors like biological differences and suggesting potential precision medicine approaches, but it reports no new clinical results.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

This study found that mice lacking alkaline ceramidase 1 with elevated skin ceramide levels showed disrupted skin homeostasis, including altered hair follicle structures, increased water loss, and a hypermetabolism phenotype.

Spironolactone might help protect against severe lung problems in COVID-19 patients.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

This review highlights the mixed roles of testosterone in COVID-19, noting both potential benefits through anti-inflammatory effects and risks due to increased virus entry, with low testosterone linked to increased severity.

This review discusses the impact of COVID-19 on the endocrine system and reports no clinical results; the authors emphasize the need to investigate endocrine damage during and after COVID-19 infection.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.